| Expression pattern: |
UP |
| Associated gene: |
YAP1, METTL3, SMAD3 |
| Associated microRNA: |
- |
| Biological function: |
Promotes CRC cell invasion and migration and EMT; promotes metastasis in vivo. |
| Molecular mechanism: |
METTL3 installs m6A modifications on circ1662 flanking sequences to induce circ1662; circ1662 directly binds YAP1 protein, reduces YAP1 Ser127 phosphorylation, and accelerates YAP1 nuclear transport, leading to inhibition of SMAD3 signaling and promotion of EMT. |
| Biological pathway or process: |
metastasis (promotes); migration (promotes); invasion (promotes); EMT (promotes); m6A modification (promotes) |
| Detected method: |
Q
H
S
|
| Validation methods: |
RNA-seq; RT-qPCR; RNase R Treatment; Actinomycin D / DRB Stability Assay; divergent primers PCR; ISH (In Situ Hybridization); FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; Transwell Assay; Wound Healing Assay; Western Blot; IF (Immunofluorescence); IHC (Immunohistochemistry); In Vivo Animal Model; H&E Staining; Clinical Sample Validation; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circ1662 expression correlated with poor prognosis and tumor depth in CRC; proposed as a prognostic and therapeutic marker for CRC metastasis. |
| Description: |
circ1662 is upregulated in colorectal cancer and promotes invasion, migration, EMT, and lung metastasis. It binds YAP1 protein and accelerates YAP1 nuclear transport, which suppresses SMAD3 signaling; METTL3-driven m6A modification enhances circ1662 biogenesis. High circ1662 expression associates with deeper tumors and poorer overall survival, supporting its prognostic/therapeutic relevance in CRC metastasis. |
| Confidence score: |
0.8801 |